Bryn Mawr Trust Advisors LLC Trims Holdings in Novartis AG $NVS

Bryn Mawr Trust Advisors LLC trimmed its holdings in shares of Novartis AG (NYSE:NVS) by 36.3% in the 1st quarter, Holdings Channel reports. The firm owned 6,002 shares of the company’s stock after selling 3,423 shares during the quarter. Bryn Mawr Trust Advisors LLC’s holdings in Novartis were worth $917,000 at the end of the most recent quarter.

Other large investors have also recently made changes to their positions in the company. Brighton Jones LLC increased its stake in Novartis by 76.5% in the 4th quarter. Brighton Jones LLC now owns 6,153 shares of the company’s stock worth $599,000 after buying an additional 2,666 shares during the period. AQR Capital Management LLC lifted its holdings in Novartis by 102.8% during the 1st quarter. AQR Capital Management LLC now owns 22,573 shares of the company’s stock valued at $2,516,000 after buying an additional 11,444 shares in the last quarter. Empowered Funds LLC purchased a new stake in Novartis in the 1st quarter valued at about $1,764,000. Sivia Capital Partners LLC boosted its position in Novartis by 48.0% in the 2nd quarter. Sivia Capital Partners LLC now owns 7,959 shares of the company’s stock valued at $963,000 after buying an additional 2,581 shares during the period. Finally, Schnieders Capital Management LLC. bought a new position in Novartis in the 2nd quarter worth about $202,000. 13.12% of the stock is owned by hedge funds and other institutional investors.

Novartis Stock Performance

NVS stock opened at $150.45 on Wednesday. Novartis AG has a 1-year low of $112.34 and a 1-year high of $170.46. The business has a 50-day moving average price of $151.06 and a 200 day moving average price of $151.40. The company has a market capitalization of $287.08 billion, a P/E ratio of 21.55, a PEG ratio of 2.64 and a beta of 0.45. The company has a debt-to-equity ratio of 0.96, a current ratio of 0.85 and a quick ratio of 0.65.

Novartis (NYSE:NVS) last issued its earnings results on Monday, April 27th. The company reported $1.99 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.11 by ($0.12). The business had revenue of $13.52 billion for the quarter, compared to the consensus estimate of $13.44 billion. Novartis had a return on equity of 38.82% and a net margin of 24.87%.The firm’s revenue was down .9% on a year-over-year basis. During the same quarter in the previous year, the company earned $2.28 earnings per share. As a group, equities research analysts forecast that Novartis AG will post 8.77 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on NVS. Morgan Stanley raised their target price on shares of Novartis from $143.00 to $170.00 and gave the stock an “overweight” rating in a research report on Thursday, March 26th. Weiss Ratings lowered Novartis from a “buy (a-)” rating to a “buy (b)” rating in a report on Wednesday, April 29th. Finally, Sanford C. Bernstein raised Novartis to a “hold” rating in a research note on Thursday, March 19th. Seven analysts have rated the stock with a Buy rating, seven have assigned a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $141.20.

Novartis Company Profile

Novartis is a Swiss multinational pharmaceutical company headquartered in Basel that researches, develops, manufactures and commercializes prescription medicines and related health-care products. Formed through the 1996 merger of Ciba-Geigy and Sandoz, Novartis operates globally and focuses on bringing therapeutics from discovery through clinical development to commercial markets worldwide.

The company’s activities center on innovative pharmaceuticals across several therapeutic areas, including oncology, immunology, cardiovascular and metabolic diseases, neuroscience and ophthalmology, alongside capabilities in advanced therapies such as biologics, cell and gene therapies.